Analystreport

Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) is now covered by analysts at Aegis. They set a "buy" rating and a $5.50 price target on the stock.

Oramed Pharmaceuticals Inc.  (ORMP) 
Last oramed pharmaceuticals inc. earnings: 4/6 04:46 pm Check Earnings Report
US:NASDAQ Investor Relations: oramed.com/investors